Literature DB >> 17847176

Empiric treatment options in the management of complicated intra-abdominal infections.

John A Weigelt1.   

Abstract

Complicated intra-abdominal infections remain a major challenge for surgeons and internists because of their association with high morbidity and mortality. For optimal outcome, these infections require a combination of appropriate and timely surgical source control and adjunctive broad-spectrum antimicrobial therapy. This review discusses criteria for choosing empiric antimicrobial therapy, outlines available treatment options, and highlights new antimicrobial therapies for these infections.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17847176     DOI: 10.3949/ccjm.74.suppl_4.s29

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  17 in total

1.  Antimicrobial Susceptibilities of Aerobic and Facultative Gram-Negative Bacilli from Intra-abdominal Infections in Patients from Seven Regions in China in 2012 and 2013.

Authors:  Hui Zhang; Qiwen Yang; Kang Liao; Yuxing Ni; Yunsong Yu; Bijie Hu; Ziyong Sun; Wenxiang Huang; Yong Wang; Anhua Wu; Xianju Feng; Yanping Luo; Zhidong Hu; Yunzhuo Chu; Shulan Chen; Bin Cao; Jianrong Su; Bingdong Gui; Qiong Duan; Shufang Zhang; Haifeng Shao; Haishen Kong; Robert E Badal; Yingchun Xu
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

2.  Efficacy and safety of moxifloxacin in hospitalized patients with secondary peritonitis: pooled analysis of four randomized phase III trials.

Authors:  Jan J De Waele; Jose M Tellado; Günter Weiss; Jeffrey Alder; Frank Kruesmann; Pierre Arvis; Tajamul Hussain; Joseph S Solomkin
Journal:  Surg Infect (Larchmt)       Date:  2014-05-15       Impact factor: 2.150

3.  CT differentiation between tubo-ovarian and appendiceal origin of right lower quadrant abscess: CT, clinical, and laboratory correlation.

Authors:  Nurith Hiller; Tal Fux; Anna Finkelstein; Haggi Mezeh; Natalia Simanovsky
Journal:  Emerg Radiol       Date:  2015-12-30

Review 4.  [Antibiotic therapy of intra-abdominal infections in the era of multiresistance].

Authors:  C Eckmann
Journal:  Chirurg       Date:  2016-01       Impact factor: 0.955

5.  A focus on intra-abdominal infections.

Authors:  Massimo Sartelli
Journal:  World J Emerg Surg       Date:  2010-03-19       Impact factor: 5.469

6.  Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial.

Authors:  Zhangjing Chen; Jufang Wu; Yingyuan Zhang; Junming Wei; Xisheng Leng; Jianwei Bi; Rong Li; Lunan Yan; Zhiwei Quan; Xiaoping Chen; Yunsong Yu; Zhiyong Wu; Dawei Liu; Xiaochun Ma; Robert Maroko; Angel Cooper
Journal:  BMC Infect Dis       Date:  2010-07-21       Impact factor: 3.090

7.  A Comprehensive review of abdominal infections.

Authors:  Nicole Lopez; Leslie Kobayashi; Raul Coimbra
Journal:  World J Emerg Surg       Date:  2011-02-23       Impact factor: 5.469

8.  WSES consensus conference: Guidelines for first-line management of intra-abdominal infections.

Authors:  Massimo Sartelli; Pierluigi Viale; Kaoru Koike; Federico Pea; Fabio Tumietto; Harry van Goor; Gianluca Guercioni; Angelo Nespoli; Cristian Tranà; Fausto Catena; Luca Ansaloni; Ari Leppaniemi; Walter Biffl; Frederick A Moore; Renato Poggetti; Antonio Daniele Pinna; Ernest E Moore
Journal:  World J Emerg Surg       Date:  2011-01-13       Impact factor: 5.469

9.  Doripenem in hospital infections: a focus on nosocomial pneumonia, complicated intra-abdominal infections, and complicated urinary tract infections.

Authors:  Tze Shien Lo; Stephanie M Borchardt; Justin M Welch; Melissa A Rohrich; Augusto M Alonto; Anne V Alonto
Journal:  Infect Drug Resist       Date:  2009-06-30       Impact factor: 4.003

10.  Antimicrobial treatment of "complicated" intra-abdominal infections and the new IDSA guidelines ? a commentary and an alternative European approach according to clinical definitions.

Authors:  Christian Eckmann; M Dryden; P Montravers; R Kozlov; G Sganga
Journal:  Eur J Med Res       Date:  2011-03-28       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.